Vitamin D3 and K2: Artery Calcium Still Rose, a Fifth Slower in the Largest Trial

“Vitamin d3 and k2 benefits” is searched about 14,800 times a month in the United States, and “vitamin k2 benefits” about 18,100 times a month, the database’s figures for the past year (from a paid keyword database, pulled 23 October 2026) [1]. The pitch behind the pair fits in one breath. Vitamin D3 helps you absorb calcium. Vitamin K2 directs that calcium into your bones and teeth and keeps it “away from soft tissues like arteries”, in the words of the K2 ingredient maker’s own page [2]. So, the story goes, D3 without K2 is a risk, and the two together build bone and protect the heart.

Calcium still built up in the arteries of people taking K2 with D3. In the largest trial of the pair, 398 people who already had heavy calcium in the heart’s arteries, it built up about a fifth more slowly than on a dummy pill over two years. In a trial of 365 men given the same pills, it did not build up significantly more slowly. Whether a slower build-up means fewer heart attacks is the part the pills are sold as having settled, and no trial of the pair that we found was built to count them [3].

The rest of the pitch fares worse, and one part of it is a real hazard. In the longest trial we found that gave K2 on top of vitamin D3 and calcium, bone density fell about as much as in the women given D3 and calcium alone [4]. And vitamin K, including K2, works against warfarin, the blood thinner [5] [6].

This is journalism, not medical advice. If you take warfarin or another vitamin K antagonist, do not start vitamin K2 without your prescriber: vitamin K changes how those drugs work, and in healthy volunteers given a drug of the same kind, as little as 10 micrograms of K2 a day was judged to lower the blood-clotting test their doses are set by, to a degree that matters, in at least 40% of them [5] [6] [7]. The NIH’s fact sheets ask anyone who takes medicines regularly to discuss their vitamin K and vitamin D with their health care provider [5] [8]. If you are pregnant or breastfeeding, or have kidney disease, the trials on this page were not done in people like you, or were done in patients under specialist care: ask a clinician or pharmacist before starting.

Does vitamin K2 keep calcium out of your arteries?

The idea starts from real biology. Vitamin K is needed to finish making a handful of proteins: the clotting factors made in the liver; osteocalcin, in bone; and matrix Gla protein, made in the artery wall, which the NIH describes as possibly helping to reduce abnormal calcification [5]. Mice bred without matrix Gla protein die within two months, their arteries calcified until the vessels rupture [9]. Vitamin K2 is not one compound but a family called menaquinones [5]. Most of the trials below used MK-7, the kind made by the bacteria that ferment natto, a Japanese soybean dish [10].

So the test is simple: give people K2, then scan their arteries. The scan used is a calcium score, a number read off a CT scan of the heart’s arteries that measures the hardened, calcified part of plaque; zero means none was seen, and the largest trial below enrolled people at 400 or more, which it called severe [11]. Here are the trials we read, largest first.

The largest is the 2026 Danish trial. It gave 400 people, 30% of them women, with a median age of 71, either 720 micrograms of K2 (MK-7) with 25 micrograms (1,000 IU) of D3 every day, or a dummy pill, for two years; 398 were analysed [11]. The calcium score rose in both groups: by 196 on the vitamins and by 248 on the dummy [11]. The difference, 52, has a confidence interval, the range the true average difference probably sits in, of 24 to 79 [11]. Fifty-two out of 248 is about a fifth, by our arithmetic. That is a positive result, and it was tested properly: the trial was set up to check a signal from an earlier one [19].

That earlier one is the 365-man trial in the second row. Its main measure was calcium in the aortic valve, and it rose by 275 on the same pills and 292 on the dummy, a gap well inside what chance would produce [12]. Calcium in the heart’s arteries did not rise significantly more slowly either [12]. In the 304 men with no known coronary heart disease, about 60% of each group already at 400 or more, it rose by 203 against 254, with a p-value of 0.089, just the wrong side of the line researchers use for “probably not chance” [13]. In the men who started at 400 or more it rose 288 against 380, which did clear the line [13]; in those who started below 400 it rose 77 against 81, with a p-value of 0.85, nowhere near it [13]. A result found in a slice of one trial is a reason to run another, and the Danish group did: the 2026 trial was sized on exactly those numbers [19], and it found the slower rise again [11].

K2 on its own has one positive trial of this kind. In 180 Dutch patients with heart disease and moderate calcium scores, 90 assigned to 360 micrograms of MK-7 a day and 90 to a dummy pill for two years (85 and 82 analysed), the median score climbed from 135 to 184 on MK-7, against 145 to 214 on the dummy, a significant difference [14]. Its authors are careful: their findings “suggest” that MK-7 “may slow calcification in noncalcified plaques”, and what that means for plaque stability “remains to be determined” [14]. A smaller, shorter trial in 68 people with type 2 diabetes, 35 on MK-7 and 33 on a dummy, found no significant difference on CT after six months [16], and a second kind of scan, which lights up calcification that is actively forming, leaned towards more of it on K2 (p = 0.06) [15].

Then there is stiffness, another thing calcium does to a vessel. In a three-year trial of 244 healthy women past the menopause, 120 given 180 micrograms of MK-7 a day and 124 a dummy, two measures of stiffness improved on MK-7 [20]. That trial was paid for by the MK-7 ingredient maker [20]. So was a later look at a 165-woman trial, done after the fact, in which stiffness rose less on MK-7 in the women past the menopause; three of its authors work for the company or its parent [21]. In 80 older people with vascular disease, 100 micrograms for six months moved neither the main measure of artery function nor stiffness significantly [22]. And in people on dialysis, where vitamin K runs short and arteries calcify fast, the K2 trials have mostly not slowed calcification; a 2026 review concludes that K2 “has not produced reproducible benefits” on CT measures of artery or valve calcium [18]. That review went to its journal in May 2026, before the two 2026 trials above were published [18].

Does a slower calcium score mean healthier arteries?

Not necessarily, and the trialists say so themselves. A calcium score counts only the hardened part of plaque, as our plaque verdict explains. In the 143 people in the Danish trial who also had a CT scan with dye, which shows the soft plaque too, total plaque rose by a similar amount on the vitamins and on the dummy; only the calcified part grew less, by 8 cubic millimetres (range 2 to 13) [11]. The 2026 review lists the problem in a table: a calcium score “cannot distinguish plaque stabilization from harmful calcification” [18].

What would settle it is counting heart attacks, strokes and deaths, and that is where the evidence runs out. The same review says that neither vitamin K1 nor K2 “has demonstrated reductions in major adverse cardiovascular events or mortality” [18]. The 365-man trial counted 10 heart and artery events on the vitamins and 10 on the dummy, and 1 death against 4 [12]. In its 304 men with no known coronary heart disease, a combined count of heart attacks, artery-opening procedures and deaths was 1.9% against 6.7%, which its authors call “hypothesis-generating” [13]. A handful of events, counted on the side of a trial built for something else, points one way. It is not a finding yet. The one trial we found with a K2 group that has reported heart and artery events as a main measure was also built for something else, and gave no D3 [3]. It assigned 132 people on dialysis with an irregular heartbeat to a warfarin-type drug, to a newer blood thinner, or to the newer blood thinner with K2 for 18 months, to see whether calcification slowed, and calcium in the heart’s arteries, the aorta and the heart valves changed by amounts not significantly different among the three groups [23]. Those who finished the 18 months kept their treatment and were followed for longer, and a second report, covering all 132, made heart and artery events its main measure: over a median of nearly two years, the K2 group’s rate of those events, 21.4 per 100 years of follow-up against 26.2, was not significantly different from that of the group on the same blood thinner alone [24].

Has anyone tested D3 plus K2 against D3 alone?

This is the heart of the sales pitch, and it is a fair question to ask of the trials, because most of them compared the vitamins with a dummy pill. A test of the pitch needs a group taking D3 alone. Among trials that have reported a measure of the arteries themselves, we found one such trial [3]. In Poland, 42 people with chronic kidney disease were assigned by computer, two to one, to 90 micrograms of K2 with 10 micrograms (400 IU) of D3, or to D3 alone, for nine months [17]. The calcium score rose by 58 on the pair and 74 on D3 alone, a difference that could easily be chance; the wall of the main neck artery thickened less on the pair, 0.06 mm against 0.14 mm [17]. Its authors concluded that K2 “does not significantly affect the progression of calcification” [17].

On bone there are more. In Denmark, 142 women with thinning bones all took D3 (38 micrograms, 1,520 IU) and calcium every day for three years, and were assigned at random to 375 micrograms of MK-7 or a dummy tablet on top; bone density fell at the hip and spine in both groups, “without differences” between them [4]. In 381 American women who all took D3 and calcium, split three ways between vitamin K1, 45 milligrams of a form of K2 called MK-4, and dummy pills for a year, bone density on MK-4 ended up no different from that on the dummy pills [25]. Smaller trials leaned the other way. In 78 Korean women over 60, 38 assigned to MK-4 on top of D3 and calcium and 40 to D3 and calcium alone, the 45 who finished six months showed density at one spinal bone up by 0.01 g/cm² on MK-4, against a fall of 0.008 [26]. In a Greek trial, dairy foods enriched with D3, calcium and MK-7 raised spine density compared with no enriched dairy, while dairy enriched with D3 and calcium alone did not; the summary does not say whether the two enriched groups differed significantly from each other [27]. And a Chinese trial of 311 men and women tested the reverse of the pitch: adding calcium and D3 to K2 “brought no additional effects” over K2 alone [28].

One Japanese trial that turns up in Google’s results for this search did find more spine density on the pair than on either vitamin alone, in 92 women split four ways [1] [29]. Its “vitamin D3” was 1-alpha-hydroxyvitamin D3 at 0.75 micrograms a day, and its K2 was 45 milligrams of MK-4 [29]. The D3 sold in supplements is a different compound, cholecalciferol [8].

Put together, the claim that you need K2 with your D3 has been tested, mostly on bone, mostly in small trials, and the longest of them found no difference in bone density with the K2 added [4]. On the arteries themselves, the one reported test we found was in 42 kidney patients [17].

Is vitamin D3 without K2 dangerous?

For artery calcium, the trials we read say no. The fear has a real root: at toxic doses, vitamin D raises blood calcium so far that, in extreme cases, calcium settles in soft tissues, including the heart’s arteries and valves [8]. In rats, high doses of vitamin D calcify the artery wall within days, and blocking vitamin K with warfarin makes it much worse [30]. Those rats were dosed to toxicity; the calcification tracked how far their blood calcium rose [30].

People taking D3 by mouth, at up to 10,000 IU a day, are a different matter, and they have been scanned. In a Canadian trial, 311 adults aged 55 to 70 were split three ways, about 100 to each dose, to take 400, 4,000 or 10,000 IU of D3 a day for three years. In the 85 who had calcium in a leg artery at the start, it grew slowly, with no sign that the dose made a difference, and nobody developed new artery calcium [31]. The same trial’s main report found bone density falling further on the higher doses: in the forearm by 2.4% on 4,000 IU and 3.5% on 10,000 IU, against 1.2% on 400, and in the shin significantly more only on 10,000; bone strength was not significantly different, and its authors write that the findings do not support a benefit of high doses for bone [32]. The US ceiling for adults is 4,000 IU a day from all sources, so 10,000 IU is two and a half times it, by our arithmetic [8]. In the Women’s Health Initiative, 754 women aged 50 to 59 who had taken calcium with 400 IU of D3, or dummy pills, for about seven years had average calcium scores of 91.6 and 100.5, a gap that could be chance [33]. The large vitamin D trials did not find more heart disease on the vitamin, as our vitamin D verdict sets out. Whether calcium pills raise heart risk is a separate, contested question that our calcium verdict weighs.

Vitamin D3 and K2 for bones: density and fractures

For the MK-7 doses in a D3-and-K2 softgel, the bone trials split. In 244 Dutch women given 180 micrograms a day or a dummy for three years, the same number, dose and length as the stiffness trial above, MK-7 slowed the age-related loss of bone density at the spine and the neck of the thigh bone, but not at the hip as a whole [34]; the MK-7 ingredient maker paid for it [34]. In 334 Norwegian women given 360 micrograms or a dummy for a year, the rate of bone loss was not significantly different [35]. The three-year Danish trial above found no difference [4]. And in the Chinese trial, 90 micrograms a day slowed bone loss at the thigh bone’s neck in women past the menopause, and not in men [28].

The fracture evidence is mostly for a different product. In Japan and other parts of Asia, 45 milligrams of MK-4 a day is used as a treatment for osteoporosis [5]. That is 500 times the 90 micrograms of MK-7 used in several trials on this page, by our arithmetic. A 2006 pooling of seven Japanese MK-4 trials reported large drops in fractures, and in 2018 its journal corrected it. Three of the seven came from one centre whose trials had since been found problematic or retracted, and the authors asked readers to use only their analysis without that centre [36]; the pooling’s senior author also wrote to the journal to alert readers [37]. In that analysis hip fractures were no longer clearly fewer: an odds ratio, a comparison of the odds of a fracture on the vitamin with the odds without it, of 0.30, with a range of 0.05 to 1.74, which includes no difference at all [36]. Spine fractures still came out lower, at 0.40 [36]. Four of the seven trials have since been retracted. The three from that centre were retracted in 2018 and 2019, one of them at the request of its own corresponding author, on the grounds that it contained fabricated trial data for which that author was responsible [38] [39] [40]. The fourth, a Japanese osteoporosis trial that included a vitamin K group, was retracted in 2025 for what the journal called “impossible data, implausible data” and other failings [41], and it is inside both of the figures the authors asked readers to use [36]. Three researchers wrote to the journal in 2018 that they were concerned the pooling’s conclusions were no longer consistent with that analysis [42].

The largest fracture trial we found, of 4,378 Japanese women with osteoporosis, gave calcium alone (2,193 women) or calcium with MK-4 (2,185) for up to four years [43] [3]. It was open-label, meaning the women knew which they were taking, though fractures were assessed blind [43]. New spine fractures, its main measure, were not significantly fewer on MK-4; a lower rate appeared only in women who already had five or more spine fractures [43]. The MK-4 capsules’ maker paid for the trial after its first two years [43]. Smaller open-label trials point the other way: in one of 241 Japanese patients with osteoporosis, 120 given MK-4 and 121 nothing for two years, there were fewer new clinical fractures on MK-4 [44].

That one trial decides the pooled answer. A 2022 pooling of K2 trials in women past the menopause found a risk ratio, the fracture rate on K2 divided by the rate without it, of 0.56 across six trials, with a range of 0.28 to 1.11, which includes no difference at all; in one of the six the comparison group took an active vitamin D drug rather than nothing [45]. Only with the 4,378-woman trial removed, 68% of all the women in that review by our arithmetic, did it become a clear 0.38 [45]. (The review’s own summary prints different figures, 0.96 and 0.43, from those in its results section, which we report here [45].) A 2019 pooling of vitamin K1 and K2 trials, corrected in 2020 to take out the trial retracted in 2025, gives an odds ratio of 0.74 for any clinical fracture, from 0.56 to 0.97; in the trials at low risk of bias it was 0.76, from 0.58 to 1.01, and for spine fractures 0.98 across all its trials [46] [47]. For spine fractures in its trials at low risk of bias the figure was 1.06, from 0.91 to 1.24: slightly more of them on vitamin K, a difference that could be chance, which its authors read as vitamin K being “unlikely to have an effect on vertebral fracture” [46]. Its authors call the evidence “insufficient to confirm” a fracture benefit [46]. For keeping bones strong, the exercise evidence is in our osteoporosis verdict.

Does vitamin K2 reduce belly fat?

The claim traces to one trial, and to one slice of it. In 214 Dutch women aged 55 to 65 given 180 micrograms of MK-7 or a dummy for three years, body composition in the group as a whole did not differ between MK-7 and the dummy, by the authors’ account [48]. In the women whose blood marker responded most, the “good responders”, belly fat fell compared with the dummy group, and the authors themselves write that a causal relation between the rise in that marker and body fat “cannot be concluded from these data” [48]. A group picked by how well it responded is not a group picked by chance. The MK-7 ingredient maker supported the trial [48].

Two newer trials looked directly. In 60 Iranian adults with type 2 diabetes, half given 200 micrograms of MK-7 and half a dummy for 12 weeks, the 45 who finished showed body fat not significantly different between the groups [49]. In young Mexican adults carrying extra weight, 22 on 100 micrograms of MK-4 and 24 on a dummy finished 12 weeks alongside diet advice, with no significant difference in body composition [50]. One small trial points the other way: in 84 Iranian women with polycystic ovary syndrome, eight weeks of 90 micrograms of MK-7 lowered body fat and waist size more than a dummy [51].

Blood sugar has a little more behind it. A 2026 pooling of eight small trials, which mixed several forms of vitamin K and most of whose trials were run in Iran, found a modest fall in fasting blood sugar and a fall in HbA1c, a three-month average of blood sugar, that its authors call large, in people with diabetes or prediabetes; they call for larger, longer and better trials [52]. In the Danish women who took MK-7 with D3 and calcium, a standard blood-test measure of insulin resistance after a year was not significantly different from the dummy group’s [53].

Vitamin D3 and K2 benefits for testosterone and skin

Testosterone rose in rats. Young male rats fed MK-4 for five weeks had more testosterone in their blood than rats on the ordinary diet [54]. We found no trial that gave K2 to men and measured their testosterone [3]. The one human trial we read that measured male hormones, in the women with polycystic ovary syndrome, found DHT, a male hormone, and the free androgen index, a measure of active male hormone, lower on MK-7, not higher [51]. Testosterone boosters have their own verdict.

For skin as the pair is sold, its look and its ageing, the only published trial we found was of a cream: 30 women applied a K2 cream to one side of the face and neck and a plain cream to the other for eight weeks, and the K2 side measured smoother [55] [3]. The company that supplied the K2 paid for it [55]. A cream on your face is not a softgel in your stomach. We found no published trial of the capsules on skin; a registered trial of K2 by mouth in children with eczema is listed as completed, with no results posted [3].

Does vitamin K2 cause blood clots?

“Does vitamin k2 cause blood clots” is searched about 720 times a month, the database’s figure for the past year, with 590 in each of the latest two months (from a paid keyword database, pulled 23 October 2026) [1]. It is a reasonable worry, since vitamin K is needed to make clotting factors. But in healthy people those factors are already “essentially fully carboxylated”, that is, finished [56], so, by our reading, extra vitamin K has little clotting machinery left to switch on. In 42 healthy adults split into seven groups, from a dummy capsule up to 360 micrograms of MK-7 a day, the authors observed “no adverse effects on thrombin generation”, a laboratory measure of how readily blood clots [56]. In 123 people on dialysis, 61 given 360 micrograms and 62 a dummy for a year, the authors found “no detectable effects” on markers of clotting activation, and no difference between the groups in blood-vessel events [57]. The US panel that sets nutrient intakes set no upper limit for vitamin K, because of its low potential for harm, and reported that no harm from vitamin K in food or supplements had been recorded [5].

Warfarin is different, and the difference is the whole point of the drug. Warfarin works by blocking vitamin K; its label lists increased vitamin K intake among the things that weaken its effect, asks for more frequent blood tests when other products are started or stopped, and tells patients to keep their vitamin K intake consistent [6]. The NIH calls the interaction “serious and potentially dangerous” [5]. MK-7 lasts a long time in the blood, and its researchers warned in 2007 that 50 micrograms a day or more could interfere with these drugs [10]; in 2013 the same group found that 10 to 20 micrograms a day was enough to lower the clotting test in many volunteers taking a warfarin-type drug, and wrote that MK-7 supplements “need to be avoided” in people on them [7].

Can I take vitamin D3 and K2 every day? And the side effects

Every trial on this page gave the vitamins every day, for as long as three years [4] [34]. For vitamin K there is no official upper limit, because of its low potential for harm [5]. The adequate intake, the amount judged to cover nearly everyone, is 120 micrograms a day for men and 90 for women, from all sources [5]. For vitamin D the US ceiling is 4,000 IU a day from everything, food and pills together [8], and cod liver oil counts toward it too. In the trials, the reported side effects were few: in the kidney trial one person stopped for bowel discomfort [17]; the large Japanese trial recorded more adverse events on MK-4 than on calcium alone, without its summary saying which [43]; the 2026 Dutch trial reported no significant adverse effects [14]. The serious side effect is the interaction above.

Can I take vitamin D with a statin?

Google’s People Also Ask box puts this question beside the others, naming the statin Crestor [1]. The NIH’s vitamin D fact sheet says high intakes of vitamin D, especially from supplements, “might reduce the potency” of three statins, atorvastatin, lovastatin and simvastatin, because they compete for the same enzyme [8]. It names them by brand as well, and Crestor is not among them [8]. Whether that settles it for you is a question for your pharmacist, who knows your doses.

Best time to take it, and for women and men

Vitamin K is absorbed along with the fat in a meal, the way the other fat-soluble vitamins are [5]. One trial on this page asked people to take their tablets with their evening meal [15]. The trials did not compare times of day.

The evidence splits by sex in an awkward way. The bone trials were almost all in women past the menopause [34] [35] [4] [25]; in the one on this page with men in it, the bone result was in women, not men [28]. The 365-man valve trial was all men, aged about 65 to 74 [12]. The largest artery trial was 30% women [11], and the Dutch one 42% [14].

Who these studies were done on

Mostly older people who already had a lot going on in their arteries: a median age of 71 and heavy calcium in the largest trial [11], men with valve calcium [12], patients with heart disease [14], people with diabetes [15] or kidney disease [17]. If you are a healthy adult with clean arteries, the artery evidence here is about other people: the K2 trials in healthy people measured stiffness, bone and blood markers, not calcium in the arteries [20] [21] [56]. If you already have a high calcium score, the 2026 Danish trial is about people like you, and it found a slower rise, not a lower score [11].

If K2 switches on the protein that guards the arteries, why don’t the trials show clean arteries?

This section is the desk’s own reasoning, and it is labelled as such. The biology says vitamin K activates a calcium-blocking protein in the artery wall. The trials say calcium kept building up on K2. Here are three ways those fit together, each rated.

Answer one: a switched-on protein is a blood test, not an artery. K2 reliably lowered the inactive form of matrix Gla protein in the blood: by 212 units (picomoles per litre) against a rise of 45 on the dummy in the 365-man trial, which then found valve calcium not significantly different [12]. The 2026 review says that blood marker is not validated as a stand-in for the outcome [18]. Both halves are measured; that the marker sells the story is our inference.

Answer two: a slower calcium score is not the same as fewer heart attacks. In the largest trial the calcified part of plaque grew less while total plaque grew about the same [11], and the Dutch trialists write that what slower calcification means for plaque stability “remains to be determined”, while the 2026 review says a calcium score cannot tell a stabilising plaque from harmful calcification [14] [18]. This is their caution, measured as far as the scans go; whether it matters for heart attacks is open.

Answer three: if K2 helps, it may help where the calcium already is. The slower rise showed up in men who started at 400 or more [13], then again in a trial built for people at 400 or more [11], and in Dutch patients with heart disease [14], while the trials in people with diabetes, in older people with vascular disease and in dialysis patients mostly did not show a benefit [16] [22] [18]. That pattern is a surmise from a handful of trials, and the dialysis trials, in people with heavy calcium, cut against it.

Put the three together and here is what we think is true, stated plainly so you can disagree with it: K2 reliably changes a blood marker and may slow calcium build-up in arteries that already carry a lot of it; whether that means fewer heart attacks is the question the pill is sold as having answered, and no one has.

What we could not find, and would like to: a trial of K2 with D3, against D3 alone, large and long enough to count heart attacks and strokes, in people who do not have kidney disease [3]. The nearest is the 2026 Danish trial, which compared the pair with a dummy pill and measured calcium, not events [11]. A registry entry for a trial starting in 2018 to compare K2 and D3 with D3 alone on the aortic valve lists its status as unknown and has posted no results [3]. A Brazilian trial’s registry record, first submitted in January 2023 with a start date of July 2022, lists three groups, K2 with D3, D3 alone and a dummy, with blood-vessel function as the main measure, and gives the trial’s status as unknown, with no results posted. A 2024 paper under the same registration number describes 53 adults randomly assigned to D3 or a dummy for eight weeks and does not mention vitamin K; whether anyone in the trial took K2, we could not tell [58]. The next large K2 trial, of 450 Danish adults with calcium in the heart’s arteries, gives MK-7 without D3 against a dummy for three years and is due to finish in February 2027; its main measure is the calcium score [59]. If you know of the trial we describe, the corrections line on this site is open.

Where “D3 needs K2” came from

The research behind the story is a 1997 experiment: mice bred without matrix Gla protein died of calcified arteries [9]. Then came people. In 2004 the Rotterdam Study, which followed 4,807 Dutch adults from the early 1990s to 2000, reported that the third who ate the most menaquinone, the K2 found in fermented foods, meat, dairy and eggs [5], had less than half the risk of dying of coronary heart disease of the third who ate the least, a relative risk of 0.43 [60]. That is an observation, not a trial. A clinic page the AI answer cites still quotes it, as a 50% cut [1]. The vitamin D half of the fear comes from rats dosed to toxicity [30].

The framing came from the industry press. In October 2013 a supplement-industry trade magazine ran the headline that the maker’s branded K2 and vitamin D “May Slow Progression of Arterial Calcification”, about the 42-patient kidney trial, then known only from a meeting abstract, and quoted the ingredient maker’s chief executive calling it “the first clinical evaluation showing that progression of arterial calcification can be prevented with supplemental vitamin K2” [61]. When the paper appeared in 2015, the calcium-score difference could be chance [17]. In 2022 a trade site headlined that K2 with D “reduces heart attack risk” [62], about the trial whose authors called their own result neutral and “hypothesis-generating” [13].

We could not trace who first said that D3 without K2 is dangerous. Today it is everywhere you search. Google’s AI answer for this search says that without enough K2, “excess calcium from D3 can accumulate in soft tissues and blood vessels”, citing clinics, the ingredient maker, a supplement brand, a video and a 2017 review [1]. That review’s authors write that combined D and K “might be” more effective than either alone, and that few trials had studied heart outcomes [63]. A symptom-checker company’s page in the same results is titled “STOP Taking Vitamin D3 Without K2! Critical Doctor’s Protocol”, published 18 March 2026 [1]. A physician’s video channel in the results has one video called “How to Use D3 and K2 to Heal Arteries” (23 September 2026) and another called “Don’t take Vitamin D3 & Vit K2 together” (29 November 2025) [1]. And a Houston wellness clinic’s post, the AI answer’s first citation, says a 2013 study in the journal Osteoporosis International found that women taking K2 and D3 had better bone density and fewer fractures “compared to those taking D3 alone” [1]. The 2013 trial of K2 in that journal, as its summary describes it, compared MK-7 with a dummy capsule, describes no D3-alone group, and reports bone density and vertebral height, not fewer fractures [34].

The product is the pair in one softgel. A national vitamin brand’s page says “Vitamin K2 supports healthy artery function” [1], and the ingredient maker’s page says K2’s ability to “prevent calcium buildup in arteries” is one of its most important benefits [2].

None of this is aimed at anyone taking the pair. The biology is real, the worry about calcium in arteries is reasonable, and the newest trials do point somewhere. It is the sellers who turned a slower-rising scan in people with heavy calcium into a promise about everyone’s arteries.

What this is rated, and what the rating covers

Preliminary — for the claim that taking vitamin K2 with D3 slows the build-up of calcium in the heart’s arteries. The one large trial that found it was in people who already had heavy calcium.

It was tested, and the results conflict. The largest trial of the pair found calcium built up about a fifth more slowly than on a dummy pill, in people who already had heavy calcium [11]; a 365-man trial of the same pills found no significant difference on the valve or the heart’s arteries [12], and in its men who started below 400 the rise was 77 against 81 [13]; K2 alone slowed the calcium score in one two-year trial [14], while a six-month trial in diabetes, which measured calcification in the leg and other arteries rather than a heart calcium score, found no significant slowing [15] [16]; and in dialysis patients the K2 trials have mostly not slowed it [18]. Calcium rose on the vitamins in every trial, and no trial of the pair that we found was built to count heart attacks [3]. The one trial we found of the pair against D3 alone that reported on the arteries was in 42 kidney patients, and its calcium-score difference could be chance [17].

Each narrower claim, rated alone, in words. That K2 with D3 keeps calcium from building up in your arteries at all, keeps it out, or clears it: Unsupported, of the tested kind; it rose on the vitamins in every trial above, and our plaque verdict rates vitamins that remove plaque the same way [11] [12]. That K2 with D3 prevents heart attacks or strokes: Preliminary; untested as a trial’s main measure for the pair, with a few events counted on the side of one trial, as many on the vitamins as on the dummy overall and fewer in one subgroup [12] [13]; K2 without D3, added to a blood thinner in dialysis patients, was not significantly different on such events in the one trial we found that has reported them as a main measure, in a report on the longer follow-up of a trial built to measure calcification [23] [24]. That D3 without K2 is dangerous to your arteries: Unsupported, of the tested kind; at doses up to 10,000 IU a day for three years, leg-artery calcium did not grow significantly faster on the higher doses [31], and the danger in the rat studies came from toxic doses [30] [8]. Doses above the US ceiling raise a separate question, for bone [32].

That K2, with or without D3, protects bone density: Preliminary; the MK-7 trials split, and the longest that added it to D3 and calcium found no difference [34] [35] [4]. That it prevents fractures: Preliminary; the case comes mostly from 45 milligrams of MK-4, whose largest trial found no significant drop in spine fractures, and whose 2006 pooling lost its hip result once one centre’s trials were set aside and still holds a trial retracted in 2025. The later poolings of vitamin K trials clear chance only without their largest trial, or with their higher-risk trials counted, and in the 2019 pooling’s trials at low risk of bias spine fractures were slightly more common on vitamin K, within what chance would produce. The MK-7 doses in a softgel were tested on bone density rather than in trials built around fractures [43] [36] [41] [45] [46] [47] [34]. That it lowers blood sugar: Preliminary; the one pooling mixed several forms of vitamin K in small trials, and a year of MK-7 in the Danish women left a measure of insulin resistance not significantly different from the dummy group’s [52] [53]. That it raises testosterone: Preliminary, on rat evidence alone [54]. That it reduces belly fat: Unsupported, of the tested kind; the three-year trial found no difference in the group as a whole [48]. That the capsules improve skin: Unsupported, of the untested kind, as far as published trials go; the one published trial we found was of a cream [55].

What is not rated here: K2 for kidney patients, which is a question for their specialists; the evidence on calcium pills, which our calcium verdict covers; tiredness, which our low vitamin D verdict covers; and the frame in the section above, which is this desk’s reasoning from the evidence rather than a result the evidence delivered. It is marked as ours so that you can weigh it as ours.

This is journalism, not medical advice. Whether to take either vitamin, at what dose, and above all alongside warfarin or another blood thinner, belongs with the prescriber or pharmacist who knows your medicines. How we read a study, and what each tier means, is set out here.